Lumos Diagnostics and RPS Diagnostics have merged to create a full-service point-of-care diagnostic development company and support the international commercialization of FebriDx.
Abbott Molecular’s VIP2000 was recognized for its innovative product design and engineering as a finalist at the prestigious Medical Design Excellence Awards (MDEAs) in New York.
PI has entered into an agreement with Imagion Biosystems, a company dedicated to improving healthcare through the earlier detection of cancer, to develop Imagion’s MagSense instrument technology.
This month’s Association for Molecular Pathology (AMP) 2018 Annual Meeting & Expo focused on the field of precision medicine. Experts from across the molecular diagnostic world gathered in San Antonio, Texas, to exchange knowledge and ideas, with the ultimate aim of creating better patient outcomes.
Atmo Biosciences, a Planet Innovation early stage venture, has signed a licensing deal with RMIT University to secure the exclusive worldwide rights to a ground-breaking ingestible gas-sensing capsule.
Lumos Diagnostics is expanding its global footprint after agreeing an ongoing manufacturing deal for a customized lateral flow reader with a California-based life sciences company.
An RMIT University researcher working with PI on technology that can test patients for bleeding or clotting disorders has been awarded more than $650,000 in NHMRC funding.
Clever Culture Systems has collected silver at the prestigious Medical Design Excellence Awards (MDEAs) for its innovative APAS Independence instrument, which Planet Innovation helped develop.
Planet Innovation today announced a partnership with Preora Healthcare Inc., pioneers in the detection of early-stage cancers, to bring to market a series of novel, low-cost, minimally invasive, highly accurate and easy-to-use cancer screening tests.
Lumos Diagnostics develops custom products for its partners using a unique combination of integrated assay and engineering capability paired with its proven reader optical technologies.
Planet Innovation’s PoC (Point-of-Care) diagnostic platform, Nplex, will benefit from further investment to develop a cloud-connected medical counter-measures device, for the rapid detection of infectious diseases.